Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03697564
Title Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
Recruitment Suspended
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Hitendra Patel
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCSD Moores Cancer Center La Jolla California 92093 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field